Bayer

Last updated January 31, 2026

432

Innovation Areas

13,147

Inventors

104

Collaborations

Tigolaner bisoxazoline parasiticide formulations: BayerRecent Research Landscape

Co-administration of incompatible parasiticides and mineral supplements leads to dosage instability and animal stress. This formulation stabilizes the chemical interface between iron salts and triazinones to enable single-dose therapeutic delivery.

What technical problems is Bayer addressing in Tigolaner bisoxazoline parasiticide formulations?

Poor active ingredient solubility

(6)evidences

Low solubility and slow dissolution rates of crystalline antiparasitic and analgesic compounds limit systemic absorption. Improving the kinetic solubility through amorphous states ensures therapeutic efficacy at lower doses.

Parasitic helminth drug resistance

(5)evidences

Existing anthelmintic treatments suffer from diminishing efficacy due to evolving parasite resistance. Developing novel chemical scaffolds like azaquinolins overcomes cross-resistance and ensures therapeutic survival.

Parasitic resistance to existing neurotoxins

(4)evidences

Inadequate delivery of active compounds to target pests within animal hosts. Improved systemic distribution ensures comprehensive protection against disease vectors.